Clinical Trials Logo
  1. Home
  2. Primary Membranous Nephropathy
  3. NCT06120673

REmission in Membranous Nephropathy International Trial (REMIT) — REMIT  

Primary Membranous Nephropathy Clinical Trial

Official title:
International, Multi-centre Randomised Clinical Trial of Obinutuzumab Versus Corticosteroid and Cyclophosphamide in Primary Membranous Nephropathy (REMIT Trial).

Clinical Trial Summary

REMIT is an investigator-initiated, international, multi-centre, prospective, randomised, open-label, parallel-group trial. A total of 224 adult participants with Primary Membranous Nephropathy (PMN) will be recruited from renal units from Australia, New Zealand Canada, Asia, Europe, United Kingdom, and other countries. Participants will be randomised to receive either corticosteroid and cyclophosphamide or obinutuzumab. The primary outcome is a ranked, composite measure based on (a) efficacy, defined as either complete or partial remission of PMN, (b) number of adverse events, and (c) quality of life.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06120673
Study type Interventional
Source The University of Queensland
Contact Peta-Anne Paul-Brent
Phone +61411 397 776
Email remit@uq.edu.au
Status Not yet recruiting
Phase Phase 3
Start date July 31, 2024
Completion date January 31, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05800873 - Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 Phase 1
Recruiting NCT05514015 - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy Phase 4
Recruiting NCT05668403 - A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy Phase 1
Recruiting NCT05696613 - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy Phase 3
Active, not recruiting NCT04629248 - A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy Phase 3
Recruiting NCT05862233 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 3
Recruiting NCT05398653 - A Clinical Study of MIL62 in Primary Membranous Nephropathy Phase 1/Phase 2
Active, not recruiting NCT05136456 - Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy Phase 2
Recruiting NCT05707377 - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy Phase 2/Phase 3